de Ruiter R, Zwama J, Raijmakers P, Yaqub M, Burchell G, Boellaard R
Ann Nucl Med. 2024; 39(2):98-149.
PMID: 39729191
PMC: 11799077.
DOI: 10.1007/s12149-024-01991-9.
de Ruiter R, Botman E, Teunissen B, Lammertsma A, Boellaard R, Raijmakers P
Front Nucl Med. 2024; 4:1406947.
PMID: 39381032
PMC: 11460293.
DOI: 10.3389/fnume.2024.1406947.
Kim H, Kang K, Chekalkin T, Park J, Chung H, Kang B
J Orthop Surg Res. 2024; 19(1):510.
PMID: 39192290
PMC: 11348569.
DOI: 10.1186/s13018-024-05011-4.
Chou T, Nabavinia M, Tram N, Rimmerman E, Patel S, Musini K
J Am Heart Assoc. 2024; 13(4):e031823.
PMID: 38353265
PMC: 11010069.
DOI: 10.1161/JAHA.123.031823.
Zamanian M, Treglia G, Abedi I
J Imaging. 2023; 9(12).
PMID: 38132692
PMC: 10744045.
DOI: 10.3390/jimaging9120274.
[F] Sodium Fluoride PET Kinetic Parameters in Bone Imaging.
Puri T, Frost M, Cook G, Blake G
Tomography. 2021; 7(4):843-854.
PMID: 34941643
PMC: 8708178.
DOI: 10.3390/tomography7040071.
Comparison of [18F] NaF PET/CT dynamic analysis methods and a static analysis method including derivation of a semi-population input function for site-specific measurements of bone formation in a population with chronic kidney disease-mineral and....
Vrist M, Bech J, Lauridsen T, Fynbo C, Theil J
EJNMMI Res. 2021; 11(1):117.
PMID: 34807325
PMC: 8609091.
DOI: 10.1186/s13550-021-00859-7.
Bone Histomorphometry and F-Sodium Fluoride Positron Emission Tomography Imaging: Comparison Between only Bone Turnover-based and Unified TMV-based Classification of Renal Osteodystrophy.
Aaltonen L, Koivuviita N, Seppanen M, Burton I, Kroger H, Loyttyniemi E
Calcif Tissue Int. 2021; 109(6):605-614.
PMID: 34137924
PMC: 8531121.
DOI: 10.1007/s00223-021-00874-9.
PET/CT in pediatric oncology.
Masselli G, de Angelis C, Sollaku S, Casciani E, Gualdi G
Am J Nucl Med Mol Imaging. 2020; 10(2):83-94.
PMID: 32419977
PMC: 7218696.
Compartmental-modelling-based measurement of murine glomerular filtration rate using F-fluoride PET/CT.
Lee H, Kang Y, Lee H, Han J, Moon B, Byun S
Sci Rep. 2019; 9(1):11269.
PMID: 31375734
PMC: 6677809.
DOI: 10.1038/s41598-019-47728-x.
Applications of PET-Computed Tomography-Magnetic Resonance in the Management of Benign Musculoskeletal Disorders.
Yoder J, Kogan F, Gold G
PET Clin. 2018; 14(1):1-15.
PMID: 30420212
PMC: 6245663.
DOI: 10.1016/j.cpet.2018.08.001.
PET-MRI for the Study of Metabolic Bone Disease.
Yoder J, Kogan F, Gold G
Curr Osteoporos Rep. 2018; 16(6):665-673.
PMID: 30284705
PMC: 6234052.
DOI: 10.1007/s11914-018-0482-4.
Is Response Assessment of Breast Cancer Bone Metastases Better with Measurement of F-Fluoride Metabolic Flux Than with Measurement of F-Fluoride PET/CT SUV?.
Azad G, Siddique M, Taylor B, Green A, ODoherty J, Gariani J
J Nucl Med. 2018; 60(3):322-327.
PMID: 30042160
PMC: 6424232.
DOI: 10.2967/jnumed.118.208710.
Site specific measurements of bone formation using [F] sodium fluoride PET/CT.
Blake G, Puri T, Siddique M, Frost M, Moore A, Fogelman I
Quant Imaging Med Surg. 2018; 8(1):47-59.
PMID: 29541623
PMC: 5835654.
DOI: 10.21037/qims.2018.01.02.
Quantitative analysis of F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myeloma.
Sachpekidis C, Hillengass J, Goldschmidt H, Anwar H, Haberkorn U, Dimitrakopoulou-Strauss A
Am J Nucl Med Mol Imaging. 2017; 7(4):148-156.
PMID: 28913153
PMC: 5596317.
Therapy assessment of bone metastatic disease in the era of radium.
Etchebehere E, Brito A, Rezaee A, Langsteger W, Beheshti M
Eur J Nucl Med Mol Imaging. 2017; 44(Suppl 1):84-96.
PMID: 28567494
DOI: 10.1007/s00259-017-3734-0.
Potential of PET-MRI for imaging of non-oncologic musculoskeletal disease.
Kogan F, Fan A, Gold G
Quant Imaging Med Surg. 2017; 6(6):756-771.
PMID: 28090451
PMC: 5219958.
DOI: 10.21037/qims.2016.12.16.
Advances in Prostate Cancer Magnetic Resonance Imaging and Positron Emission Tomography-Computed Tomography for Staging and Radiotherapy Treatment Planning.
Moghanaki D, Turkbey B, Vapiwala N, Ehdaie B, Frank S, McLaughlin P
Semin Radiat Oncol. 2016; 27(1):21-33.
PMID: 27986208
PMC: 5743235.
DOI: 10.1016/j.semradonc.2016.08.008.
Comparisons between glucose analogue 2-deoxy-2-((18)F)fluoro-D-glucose and (18)F-sodium fluoride positron emission tomography/computed tomography in breast cancer patients with bone lesions.
Capitanio S, Bongioanni F, Piccardo A, Campus C, Gonella R, Tixi L
World J Radiol. 2016; 8(2):200-9.
PMID: 26981229
PMC: 4770182.
DOI: 10.4329/wjr.v8.i2.200.
The role of 18F-NaF PET/CT in metastatic bone disease.
Araz M, Aras G, Kucuk O
J Bone Oncol. 2015; 4(3):92-7.
PMID: 26587375
PMC: 4648995.
DOI: 10.1016/j.jbo.2015.08.002.